CE15 - Immunologie, Infectiologie et Inflammation 2023

Decrypting MHC class I trafficking in cross-presentation – Class1Cross

Submission summary

Cross-presentation of antigens internalized by dendritic cells (DCs) is critical for priming of CD8+ T cell responses to pathogens and tumors, and for immune tolerance. Despite many published studies, the trafficking pathways and loading compartments for cross-presentation by MHC-I molecules remain unclear. Preliminary evidence suggests that cross-presentation may employ diverse sources of MHC-I sources and trafficking pathways, including newly synthesized MHC-I molecules routed through conventional and non-conventional secretory and/or Golgi-to-endosome pathways, but also MHC-I stores in different subtypes of endosomes and recycling MHC-I molecules, depending on the antigen entry route and the cell type investigated.
This project will bring together two teams with documented strong expertise in studying trafficking of MHC-I molecules. The teams will employ their complementary expertise together with an array of cross-presentation assays to decipher the origin, loading compartments, and travel to the cell surface of MHC-I molecules loaded with cross-presented peptides derived from two antigens (ovalbumin and insulin) internalized by distinct mechanisms (phagocytose, mannose receptor endocytosis, Fc receptor endocytosis, pinocytosis). The development of novel assays using the RUSH (retention using selective hooks) and SpyTag/SpyCatcher systems will enable the teams to study synchronized intracellular trafficking as well as internalization of covalently labeled cell surface MHC-I molecules. If possible, the impact of key trafficking pathways will be assessed using conditional deletion models disabling antitumor vaccination in vivo. Ultimately, the results obtained might be instrumental for pharmacological manipulation of cross-presentation with the objective to up-regulate antitumor immune responses or target antigens into specific processing pathways but also to down-regulate cross-presentation of self-antigens and consequently autoimmune inflammation.

Project coordination

Peter VAN ENDERT (Institut National de la Santé et de la Recherche Médicale)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partnership

INSERM - UMR 1151 Institut National de la Santé et de la Recherche Médicale

Help of the ANR 333,587 euros
Beginning and duration of the scientific project: March 2024 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter